Pub-2010

Articles

Title
Bortezomib as a Treatment Option in Patients With Waldenstrom Macroglobulinemia.
Elevated IL-17 produced by Th17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma
Fcy Receptor Predictive Genomic Testing and the Treatment of Indolent Non-Hodgkin Lymphoma
IgA and IgG hypogammaglobulinemia in Waldenström's macroglobulinemia.
Phase II Trial of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Relapsed or Refractory Waldenstrom Macroglobulinemia
Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory Waldenstrom Macroglobulinemia.
Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia.